Boehringer and Kyowa Kirin sign fibro-inflammatory treatment deal
2024-01-08
引进/卖出免疫疗法临床3期
Preview
来源: Pharmaceutical Technology
Boehringer Ingelheim intends to create breakthrough therapies’to enhance patient outcomes. Credit: Boehringer Ingelheim International.
Boehringer Ingelheim has signed a licensing agreement with Japan’s Kyowa Kirin to develop a new treatment for fibro-inflammatory diseases.
The deal aligns with Boehringer Ingelheim’s strategy to create breakthrough therapies in this disease area to enhance patient outcomes.
Boehringer Ingelheim will receive exclusive rights from the Japanese pharmaceutical and biotechnology company to develop treatments globally.
Kyowa Kirin will receive €410m, including an upfront payment and additional success-based milestones, along with sales royalties.
Kyowa Kirin senior managing executive officer, chief medical officer and board director Takeyoshi Yamashita stated: “We are pleased to announce that we have signed the licence agreement with Boehringer Ingelheim.
“The compound was discovered through Kyowa Kirin’s expertise in innovative technology and disease biology. Boehringer Ingelheim is highly regarded for its expertise in fibro-inflammatory diseases, and we believe that it should be the best partner to maximise and deliver the value of our compound for patients in need.”
Fibro-inflammatory diseases, which include conditions such as systemic sclerosis and lung fibrosis, are caused by chronic inflammation and are a significant source of morbidity and mortality globally.
Such diseases severely affect a patient’s quality of life and are responsible for more than one-third of deaths worldwide.
Boehringer Ingelheim corporate senior vice-president and discovery research global head Clive Wood stated: “We are very excited about partnering with Kyowa Kirin and being able to add this opportunity to our portfolio to develop breakthrough treatments for patients with this new collaboration.”
Boehringer is conducting Phase III clinical trials for BI 1015550, a PDE4B inhibitorPDE4B inhibitor, targeting idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases.
Boehringer recently signed a partnership and licensing agreement with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。